{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059101","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.456621+00:00","generated_at":"2026-06-02T05:25:54.503213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ironwood Q1 revenue down 28% YoY, net loss $4.2M; apraglutide Phase III positive","bullets":["Q1 total revenue $74.9M vs $104.1M YoY; GAAP net loss of $4.2M vs net income of $45.7M.","LINZESS prescription demand grew 10% YoY; revenue impacted by gross-to-net change.","Positive Phase III STARS trial of apraglutide in SBS-IF; NDA filing planned.","Revised FY 2024 guidance due to LINZESS gross-to-net change estimate.","Adjusted EBITDA fell to $12.8M from $60.4M YoY; non-GAAP net loss per share $(0.02)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059101","json":"https://secwatch.observer/filing/0001104659-24-059101.json","markdown":"https://secwatch.observer/filing/0001104659-24-059101.md","text":"https://secwatch.observer/filing/0001104659-24-059101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/0001104659-24-059101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/tm2413858d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:25:54.503213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d939bfa9d55f0d14bae0b8493401e0f2aa0cfe43","claim":"IRONWOOD PHARMACEUTICALS INC reported first quarter 2024 results: revenue $74,877, net income $(4,162), EPS $(0.03).","evidence_excerpt":"growth, and delivering sustained profits and cash flow.” First Quarter 2024 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2024 Q1 2023 Total revenue 2 $ 74,877 $ 104,061 Total operating expenses 63,857 43,964 GAAP net income (loss) 2 (4,162 ) 45,714 GAAP net income (loss) – per share basic 2 (0.03 ) 0.30 GAAP net income (loss) – per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/0001104659-24-059101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$74,877"},{"label":"Net income","value":"$(4,162)"},{"label":"EPS","value":"$(0.03)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}